Research programme: RNA virus infection therapeutics - Alivexis
Alternative Names: Research programme: antivirals - AlivexisLatest Information Update: 16 Apr 2024
At a glance
- Originator Modulus Discovery
- Developer Alivexis
- Class Antivirals; Small molecules
- Mechanism of Action Genetic transcription modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Viral infections
Most Recent Events
- 24 Aug 2023 RNA virus infection therapeutics is available for licensing as of 24 Aug 2023. https://modulusdiscovery.com/ (Modulus Discovery pipeline, August 2023)
- 24 Aug 2023 Early research in Viral infections in Japan (unspecified route) prior to August 2023 (Modulus Discovery pipeline, August 2023)
- 02 Oct 2020 Modulus Discovery enters into a research collaboration with University of Tokyo to pursue drug discovery on a novel target for COVID-19 and related emerging virus infections